| 000 | 01550 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517144618.0 | ||
| 264 | 0 | _c20171120 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a0392-856X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYang, Min | |
| 245 | 0 | 0 |
_aEffectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world. _h[electronic resource] |
| 260 |
_bClinical and experimental rheumatology _c |
||
| 300 |
_a791-798 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAdalimumab _xadministration & dosage |
| 650 | 0 | 4 | _aAdministrative Claims, Healthcare |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdiagnosis |
| 650 | 0 | 4 |
_aBiological Products _xadministration & dosage |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 |
_aEtanercept _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aGalebach, Philip J | |
| 700 | 1 | _aSignorovitch, James E | |
| 700 | 1 | _aGarg, Vishvas | |
| 773 | 0 |
_tClinical and experimental rheumatology _gvol. 35 _gno. 5 _gp. 791-798 |
|
| 999 |
_c27012549 _d27012549 |
||